Cytotoxic T-cell lymphoma presenting as secondary myelofibrosis with high levels of PDGF and TGF-beta

Eur J Haematol. 2001 Mar;66(3):210-2. doi: 10.1034/j.1600-0609.2001.00302.x.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / blood*
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Immunophenotyping
  • Lymphoma, T-Cell, Peripheral / blood
  • Lymphoma, T-Cell, Peripheral / complications
  • Lymphoma, T-Cell, Peripheral / diagnosis*
  • Lymphoma, T-Cell, Peripheral / drug therapy
  • Lymphoma, T-Cell, Peripheral / pathology
  • Lymphoma, T-Cell, Peripheral / therapy
  • Neoplasm Proteins / blood*
  • Pancytopenia / etiology
  • Platelet-Derived Growth Factor / analysis*
  • Prednisolone / administration & dosage
  • Primary Myelofibrosis / etiology*
  • Remission Induction
  • T-Lymphocytes, Cytotoxic / pathology*
  • Transforming Growth Factor beta / blood*
  • Transplantation, Homologous
  • Vincristine / administration & dosage

Substances

  • Biomarkers, Tumor
  • Neoplasm Proteins
  • Platelet-Derived Growth Factor
  • Transforming Growth Factor beta
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone